Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLD200 (Jornay PM) efficacy in children with ADHD in a classroom setting
NCT02493777Phase 3Completed
- Sponsor
- Ironshore Pharmaceuticals
- Start
- Jul 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of methylphenidate in attention deficit hyperactivity disorder (ADHD), sponsored by Ironshore Pharmaceuticals. Started Jul 2015; status: completed.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02493777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02493777.